Literature DB >> 24702012

Next generation medical therapy for Cushing's syndrome--can we measure a benefit?

Peter J Trainer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24702012     DOI: 10.1210/jc.2014-1054

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  2 in total

1.  Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.

Authors:  Eleni Daniel; Simon Aylwin; Omar Mustafa; Steve Ball; Atif Munir; Kristien Boelaert; Vasileios Chortis; Daniel J Cuthbertson; Christina Daousi; Surya P Rajeev; Julian Davis; Kelly Cheer; William Drake; Kirun Gunganah; Ashley Grossman; Mark Gurnell; Andrew S Powlson; Niki Karavitaki; Isabel Huguet; Tara Kearney; Kumar Mohit; Karim Meeran; Neil Hill; Aled Rees; Andrew J Lansdown; Peter J Trainer; Anna-Elisabeth H Minder; John Newell-Price
Journal:  J Clin Endocrinol Metab       Date:  2015-09-09       Impact factor: 5.958

Review 2.  Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.